Document Detail


Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy.
MedLine Citation:
PMID:  22899879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1 ± 3.9%; median: 5.7% at day 14, and mean ± SD: 7.4 ± 2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5 ± 4.0%; median: 3.6%; P = 0.03 and P < 0.001, resp.). Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69 ± 0.21 mm) were compared with those found at day 0 (0.65 ± 0.16 mm) (P = 0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA.
Authors:
Carlos Gonzalez-Juanatey; Tomas R Vazquez-Rodriguez; Jose A Miranda-Filloy; Ines Gomez-Acebo; Ana Testa; Carlos Garcia-Porrua; Amalia Sanchez-Andrade; Javier Llorca; Miguel A González-Gay
Related Documents :
18463929 - Vagotomy during hiatal hernia repair: a benign esophageal lengthening procedure.
19692879 - Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for acute...
10931019 - Laparoscopic compared with open methods of groin hernia repair: systematic review of ra...
10512939 - Tension-free laparoscopic and open hernia repair: randomized controlled trial of early ...
4013599 - Long-term results after incisional hernia repair.
12820029 - Sutureless lichtenstein: first results of a prospective randomised clinical trial.
24720919 - Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospe...
22580859 - Estimation of botulinum toxin type a efficacy on spasticity and functional outcome in c...
3134359 - The use of indomethacin to prevent the formation of heterotopic bone after total hip re...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-31
Journal Detail:
Title:  Mediators of inflammation     Volume:  2012     ISSN:  1466-1861     ISO Abbreviation:  Mediators Inflamm.     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-17     Completed Date:  2012-11-28     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  9209001     Medline TA:  Mediators Inflamm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  674265     Citation Subset:  IM    
Affiliation:
Cardiology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, Spain. carlosjuanatey@secardiologia.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  physiopathology
Carotid Intima-Media Thickness
Endothelium, Vascular / drug effects,  pathology*
Female
Humans
Middle Aged
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; FYS6T7F842/adalimumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Possible roles of proinflammatory and chemoattractive cytokines produced by human fetal membrane cel...
Next Document:  Endoscopic Functional Fourier Domain Common Path Optical Coherence Tomography for Microsurgery.